COMPLIANCE: OIG Wants To Squeeze Your Drug Payments Further
Doxorubic and Interferon are at the top of the hit list.Warning: Your already low payments for Part B drugs could wind up slashed even further, if the HHS Office of Inspector General (OIG) gets its way. The OIG has been beating a drum on Part B drug payments for years, even after Medicare switched to a lowball system based on 106 percent of the Average Sales Price (ASP), or the manufacturer's regular price. In its latest report (OEI-03-07-00140), the OIG compared that amount with the amount wholesalers--who buy in bulk--pay for the drugs.Not surprisingly, the...
To read the full article, sign in and subscribe to tci Medicare Compliance & Reimbursement.
Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.
Current newsletters added each month
Fully searchable archives - over 4200 articles
ALL years/issues back to 2003 organized by year and issue
Codes mentioned in articles are linked to Code Information pages
Code Information pages link back to related articles
Access to this feature is available in the following products: